Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

Published September 8, 2026 · Category: Finance

Overview

Pfizer (NYSE: PFE) has one of the highest dividend yields of any pharmaceutical stock -- 6.1% at its current share price. That's more than twice the yield that AbbVie (NYSE: ABBV) offers, but in the long run, I believe AbbVie is the better dividend stock.

Pfizer has slightly outperformed AbbVie this year, with a return of over 14% compared to more than 12% for AbbVie. However, in terms of revenue growth, AbbVie has grown by more than 138% over the past decade, while Pfizer's revenue is up just over 18% over that period.

Details

Here are three more reasons why I prefer AbbVie as the better dividend stock.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.